Skip to main content
Erschienen in: Cardiovascular Intervention and Therapeutics 1/2023

02.08.2022 | Original Article

Two-year results of endovascular therapy for femoropopliteal artery disease in Japan during the introduction of drug-eluting devices

verfasst von: Kenji Suzuki, Daisuke Ueshima, Michiaki Higashitani, Yasutaka Yamauchi, Koji Hozawa, Naoki Hayakawa, Kazuki Tobita, Kenji Ogata, Takahiro Ohmine, Masato Nakamura

Erschienen in: Cardiovascular Intervention and Therapeutics | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Although various devices and strategies were introduced into endovascular therapy, factors associated with chronic outcomes remain unclear. Therefore, this study aimed to build preliminary data of Japanese femoropopliteal lesions in a period of transition from non-drug to drug technology. This research was a multicenter, prospective, and observational study. A total of 1003 consecutive patients with a mean age of 73.6 ± 8.3 years from 67 institutes were registered from February 2017 to June 2018 in Japan. In addition to the baseline data, angiographic findings affecting primary patency were studied. Lesion length was 16.4 ± 9.6 cm, and chronic total occlusion was found in 42%. Calcified lesions were found in 75% of patients. The 1-year and 2-year freedom from target lesion revascularization were 81% and 75%, respectively, and maximum walking distance showed improvement over the two years (pre; 234 m ± 211 m, 1-year; 402 m ± 241 m, 2-year; 428 m ± 231 m). The independent predictors for primary patency were pre-procedure ankle-brachial index, history of minor amputation, ostium lesion, and drug-coated balloon use. Angiographic analysis revealed that only lesion length and full cover stent were related to primary patency. Two-year freedom from target vessel revascularization was 75% in the Japanese transitional period of drug-eluting devices. Maximum walking distance was improved and well maintained for up to 2-year.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bunte MC, Cohen DJ, Jaff MR, Gray WA, Magnuson EA, Li H, et al. Long-term clinical and quality of life outcomes after stenting of femoropopliteal artery stenosis: 3-year results from the STROLL study. Catheter Cardiovasc Interv. 2018;92:106–14.CrossRef Bunte MC, Cohen DJ, Jaff MR, Gray WA, Magnuson EA, Li H, et al. Long-term clinical and quality of life outcomes after stenting of femoropopliteal artery stenosis: 3-year results from the STROLL study. Catheter Cardiovasc Interv. 2018;92:106–14.CrossRef
2.
Zurück zum Zitat Iida O, Tkahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, et al. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II Class A to C and D lesions in the femoropopliteal artery. J Am Coll Cardiol Intv. 2014;7:792–8.CrossRef Iida O, Tkahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, et al. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II Class A to C and D lesions in the femoropopliteal artery. J Am Coll Cardiol Intv. 2014;7:792–8.CrossRef
3.
Zurück zum Zitat Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol. 2009;53:48–53.CrossRef Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol. 2009;53:48–53.CrossRef
4.
Zurück zum Zitat Nordanstig J, Taft C, Hensater M, Perlander A, Österberg K, Jivegård L. Two-year results from a randomized clinical trial of revascularization in patients with intermittent claudication. Br J Surg. 2016;103:1290–9.CrossRef Nordanstig J, Taft C, Hensater M, Perlander A, Österberg K, Jivegård L. Two-year results from a randomized clinical trial of revascularization in patients with intermittent claudication. Br J Surg. 2016;103:1290–9.CrossRef
6.
Zurück zum Zitat Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger C, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–53.CrossRef Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger C, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–53.CrossRef
7.
Zurück zum Zitat Ichihashi S, Shibata T, Fujimura N, Nagatomi S, Yamamoto H, Kyuragi R, et al. Vessel calcification as a risk factor for in-stent restenosis in complex femoropopliteal lesions after Zilver PTX paclitaxel-coated stent placement. J Endovasc Ther. 2019;26:613–20.CrossRef Ichihashi S, Shibata T, Fujimura N, Nagatomi S, Yamamoto H, Kyuragi R, et al. Vessel calcification as a risk factor for in-stent restenosis in complex femoropopliteal lesions after Zilver PTX paclitaxel-coated stent placement. J Endovasc Ther. 2019;26:613–20.CrossRef
8.
Zurück zum Zitat Fujihara M, Kozuki A, Tsubakimoto Y, Takahara M, Shintani Y, Fukunaga M, et al. Lumen gain after endovascular therapy in calcified superficial femoral artery occlusive disease assessed by intravascular ultrasound (CODE Study). J Endovasc Ther. 2019;26:322–30.CrossRef Fujihara M, Kozuki A, Tsubakimoto Y, Takahara M, Shintani Y, Fukunaga M, et al. Lumen gain after endovascular therapy in calcified superficial femoral artery occlusive disease assessed by intravascular ultrasound (CODE Study). J Endovasc Ther. 2019;26:322–30.CrossRef
9.
Zurück zum Zitat Fanelli F, Cannavale A, Gazzetti M, Lucatelli P, Wlderk A, Cirelli C, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898–907.CrossRef Fanelli F, Cannavale A, Gazzetti M, Lucatelli P, Wlderk A, Cirelli C, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898–907.CrossRef
10.
Zurück zum Zitat Tsukiyama Y, Konishi A, Shinke T, Kozuki A, Otake H, Kawamori H, et al. Open-label multicenter registry on the outcomes of peripheral arterial disease treated by balloon angioplasty with optical frequency domain imaging in superficial femoral artery and popliteal artery (OCEAN-SFA study). Cardiovasc Interv Ther. 2021;36:321–9.CrossRef Tsukiyama Y, Konishi A, Shinke T, Kozuki A, Otake H, Kawamori H, et al. Open-label multicenter registry on the outcomes of peripheral arterial disease treated by balloon angioplasty with optical frequency domain imaging in superficial femoral artery and popliteal artery (OCEAN-SFA study). Cardiovasc Interv Ther. 2021;36:321–9.CrossRef
11.
Zurück zum Zitat Soga Y, Takahara M, Ito N, Katsuki T, Imada K, Hiramori S, et al. Clinical impact of intravascular ultrasound-guided balloon angioplasty in patients with chronic limb threatening ischemia for isolated infrapopliteal lesion. Catheter Cardiovasc Interv. 2021;97:E376–84.CrossRef Soga Y, Takahara M, Ito N, Katsuki T, Imada K, Hiramori S, et al. Clinical impact of intravascular ultrasound-guided balloon angioplasty in patients with chronic limb threatening ischemia for isolated infrapopliteal lesion. Catheter Cardiovasc Interv. 2021;97:E376–84.CrossRef
12.
Zurück zum Zitat Fujihara M, Yazu Y, Takahara M. Intravascular ultrasound-guided interventions for below-the-knee disease in patients with chronic limb-threatening ischemia. J Endovasc Ther. 2020;27:565–74.CrossRef Fujihara M, Yazu Y, Takahara M. Intravascular ultrasound-guided interventions for below-the-knee disease in patients with chronic limb-threatening ischemia. J Endovasc Ther. 2020;27:565–74.CrossRef
13.
Zurück zum Zitat Fujihara M, Tkahara M, Sasaki S, Nanto K, Utsunomiya M, Iida O, et al. Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease. J Endovasc Ther. 2017;24:367–75.CrossRef Fujihara M, Tkahara M, Sasaki S, Nanto K, Utsunomiya M, Iida O, et al. Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease. J Endovasc Ther. 2017;24:367–75.CrossRef
14.
Zurück zum Zitat Kobayashi N, Hirano K, Yamawaki M, Araki M, Sakai T, Sakamoto Y, et al. Simple classification and clinical outcomes of angiographic dissection after balloon angioplasty for femoropopliteal disease. J Vasc Surg. 2018;67:1151–8.CrossRef Kobayashi N, Hirano K, Yamawaki M, Araki M, Sakai T, Sakamoto Y, et al. Simple classification and clinical outcomes of angiographic dissection after balloon angioplasty for femoropopliteal disease. J Vasc Surg. 2018;67:1151–8.CrossRef
15.
Zurück zum Zitat Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–83.CrossRef Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–83.CrossRef
16.
Zurück zum Zitat Suzuki K, Takahara M, Shintani Y, Tanaka A, Soga Y, Yamaoka T, et al. Retrospective multicenter comparison of SMART. CONTROL and MISAGO stents in treatment of femoropopliteal lesions. J Vasc Interv Radiol 2016;27:1642–1649. Suzuki K, Takahara M, Shintani Y, Tanaka A, Soga Y, Yamaoka T, et al. Retrospective multicenter comparison of SMART. CONTROL and MISAGO stents in treatment of femoropopliteal lesions. J Vasc Interv Radiol 2016;27:1642–1649.
17.
Zurück zum Zitat Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015;131:495–502. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015;131:495–502.
18.
Zurück zum Zitat Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16–23.CrossRef Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16–23.CrossRef
19.
Zurück zum Zitat Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis 2-year follow-up. J Am Coll Cardiol Intv. 2014;7:411–5.CrossRef Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis 2-year follow-up. J Am Coll Cardiol Intv. 2014;7:411–5.CrossRef
20.
Zurück zum Zitat Horie K, Tanaka A, Suzuki K, Taguri M, Inoue N. Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in femoropopliteal lesions. CVIR Endovasc. 2021;4:13.CrossRef Horie K, Tanaka A, Suzuki K, Taguri M, Inoue N. Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in femoropopliteal lesions. CVIR Endovasc. 2021;4:13.CrossRef
21.
Zurück zum Zitat Diem C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053–61.CrossRef Diem C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053–61.CrossRef
22.
Zurück zum Zitat Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) Study. Circulation. 2012;125:130–9.CrossRef Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) Study. Circulation. 2012;125:130–9.CrossRef
23.
Zurück zum Zitat Giannopoulos S, Stobel A, Rudofker E, Kovach C, Schneider PA, Armstrong EJ, et al. Association of postangioplasty femoropopliteal dissections with outcomes after drug-coated balloon angioplasty in the femoropopliteal arteries. J Endovasc Ther. 2021;28:593–603.CrossRef Giannopoulos S, Stobel A, Rudofker E, Kovach C, Schneider PA, Armstrong EJ, et al. Association of postangioplasty femoropopliteal dissections with outcomes after drug-coated balloon angioplasty in the femoropopliteal arteries. J Endovasc Ther. 2021;28:593–603.CrossRef
24.
Zurück zum Zitat Hong SJ, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, et al. Outcomes of spot stenting versus long stenting after intentional subintimal approach for long chronic total occlusions of the femoropopliteal artery. J Am Coll Cardiol Intv. 2015;8:472–80.CrossRef Hong SJ, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, et al. Outcomes of spot stenting versus long stenting after intentional subintimal approach for long chronic total occlusions of the femoropopliteal artery. J Am Coll Cardiol Intv. 2015;8:472–80.CrossRef
25.
Zurück zum Zitat Iida O, Takahara M, Soga Y. A novel angiographic risk score for femoropopliteal interventions. J Endovasc Ther. 2020;6:967–73.CrossRef Iida O, Takahara M, Soga Y. A novel angiographic risk score for femoropopliteal interventions. J Endovasc Ther. 2020;6:967–73.CrossRef
26.
Zurück zum Zitat Kum S, Ipema J, Huizing E, Tan YK, Lim D, Lok IY, et al. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia. Vas Med. 2021;3:267–72.CrossRef Kum S, Ipema J, Huizing E, Tan YK, Lim D, Lok IY, et al. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia. Vas Med. 2021;3:267–72.CrossRef
27.
Zurück zum Zitat Suzuki K, Iida O, Soga Y, Hirano K, Inoue N, Uematsu M, et al. Long-term results of the SMART Control™ stent for superficial femoral artery lesions. J-SMART Registry Circ J. 2011;75:939–44. Suzuki K, Iida O, Soga Y, Hirano K, Inoue N, Uematsu M, et al. Long-term results of the SMART Control™ stent for superficial femoral artery lesions. J-SMART Registry Circ J. 2011;75:939–44.
28.
Zurück zum Zitat Sato K, Iida O, Takahara M, Soga Y, Suzuki K, Tanigawa T, et al. Effect of perioperative complications after endovascular therapy in patients with peripheral artery disease due to femoropopliteal lesions. J Vasc Surg. 2015;61:1272–7.CrossRef Sato K, Iida O, Takahara M, Soga Y, Suzuki K, Tanigawa T, et al. Effect of perioperative complications after endovascular therapy in patients with peripheral artery disease due to femoropopliteal lesions. J Vasc Surg. 2015;61:1272–7.CrossRef
29.
Zurück zum Zitat Kurata N, Iida O, Asai M, Masuda M, Okamoto S, Ishihara T, et al. Factors influencing in-stent occlusion after femoropopliteal artery stent placement with intravascular ultrasound evaluation. J Vasc Interv Radiol. 2020;31:213–20.CrossRef Kurata N, Iida O, Asai M, Masuda M, Okamoto S, Ishihara T, et al. Factors influencing in-stent occlusion after femoropopliteal artery stent placement with intravascular ultrasound evaluation. J Vasc Interv Radiol. 2020;31:213–20.CrossRef
30.
Zurück zum Zitat Hong SJ, Mintz GS, Ahn CM, Kim JS, Kim BK, Ko YG, et al. Effect of intravascular ultrasound-guided drug-eluting stent implantation: 5-year follow-up of the IVUS-XPL randomized trial. JACC Cardiovasc Interv. 2020;13:62–71.CrossRef Hong SJ, Mintz GS, Ahn CM, Kim JS, Kim BK, Ko YG, et al. Effect of intravascular ultrasound-guided drug-eluting stent implantation: 5-year follow-up of the IVUS-XPL randomized trial. JACC Cardiovasc Interv. 2020;13:62–71.CrossRef
31.
Zurück zum Zitat Frohlich GM, Redwood S, Rakhit R, MacCarthy PA, Lim P, Crake T, et al. Long-term survival in patients undergoing percutaneous interventions with or without intracoronary pressure wire guidance or intracoronary ultrasonographic imaging: a large cohort study. JAMA intern Med. 2014;174:1360–6.CrossRef Frohlich GM, Redwood S, Rakhit R, MacCarthy PA, Lim P, Crake T, et al. Long-term survival in patients undergoing percutaneous interventions with or without intracoronary pressure wire guidance or intracoronary ultrasonographic imaging: a large cohort study. JAMA intern Med. 2014;174:1360–6.CrossRef
32.
Zurück zum Zitat Mori S, Hirano K, Yamawaki M, Kobayashi N, Sakamoto Y, Tsutsumi M, et al. Usefulness of ultrasound-guided intraluminal approach for long occlusive femoropopliteal lesion. Heart Vessels. 2021;36:376–82.CrossRef Mori S, Hirano K, Yamawaki M, Kobayashi N, Sakamoto Y, Tsutsumi M, et al. Usefulness of ultrasound-guided intraluminal approach for long occlusive femoropopliteal lesion. Heart Vessels. 2021;36:376–82.CrossRef
33.
Zurück zum Zitat Mustapha JA, Diaz-Sandoval LJ. Extravascular ultrasound guidance for CTO crossing. Endovascular Today 2015:56–66. Mustapha JA, Diaz-Sandoval LJ. Extravascular ultrasound guidance for CTO crossing. Endovascular Today 2015:56–66.
Metadaten
Titel
Two-year results of endovascular therapy for femoropopliteal artery disease in Japan during the introduction of drug-eluting devices
verfasst von
Kenji Suzuki
Daisuke Ueshima
Michiaki Higashitani
Yasutaka Yamauchi
Koji Hozawa
Naoki Hayakawa
Kazuki Tobita
Kenji Ogata
Takahiro Ohmine
Masato Nakamura
Publikationsdatum
02.08.2022
Verlag
Springer Nature Singapore
Erschienen in
Cardiovascular Intervention and Therapeutics / Ausgabe 1/2023
Print ISSN: 1868-4300
Elektronische ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-022-00873-z

Weitere Artikel der Ausgabe 1/2023

Cardiovascular Intervention and Therapeutics 1/2023 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.